[Effect of chemotherapy on the nucleoside phosphate kinase activity in experimental tumors].
In animals with experimental transplantable tumors, an effective treatment with antitumor compounds brought about interrelated changes in nucleoside phosphate kinase activity. The decrease in thymidine phosphate kinase activity was as a rule matched by an increase in that of uridine phosphate kinase. Consequently, "thymidine kinase-uridine kinase" shunt responsible for thymidine-uridine interconversion was suggested, which is switched on when the homeostasis of tumor cells is disturbed. In treatment of tumor-bearing animals, the effective dosage of antitumor drugs was considerably decreased due to a combination of the said compounds (inhibiting nucleoside kinases) or with azauridine which inhibits uridine monophosphate synthesis from orotidine-5'-phosphate.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D010770:Phosphotransferases / Q000378:metabolism*; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000201:enzymology; D013937:Thymidine Kinase / Q000378:metabolism*; D014541:Uridine Kinase / Q000378:metabolism*
D000970:Antineoplastic Agents; D010770:Phosphotransferases; D013937:Thymidine Kinase; D014541:Uridine Kinase
Vliianie khimioterapii na nukleozidfosfatkinaznuiu aktivnost' éksperimental'nykh opukholeĭ.